WO1998004569A1 - Analogues de nucleotides - Google Patents

Analogues de nucleotides Download PDF

Info

Publication number
WO1998004569A1
WO1998004569A1 PCT/US1997/013244 US9713244W WO9804569A1 WO 1998004569 A1 WO1998004569 A1 WO 1998004569A1 US 9713244 W US9713244 W US 9713244W WO 9804569 A1 WO9804569 A1 WO 9804569A1
Authority
WO
WIPO (PCT)
Prior art keywords
compound
alkyl
pmpa
aryl
compounds
Prior art date
Application number
PCT/US1997/013244
Other languages
English (en)
Inventor
Murty N. Arimilli
Kenneth C. Cundy
Joseph P. Dougherty
Choung U. Kim
Reza Oliyai
Valentino J. Stella
Original Assignee
Gilead Sciences, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26696272&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO1998004569(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority to DE69722004T priority Critical patent/DE69722004T2/de
Priority to JP50831898A priority patent/JP4033494B2/ja
Priority to DE122008000033C priority patent/DE122008000033I1/de
Priority to DE200512000041 priority patent/DE122005000041I2/de
Priority to EP97936257A priority patent/EP0915894B1/fr
Priority to DK97936257T priority patent/DK0915894T3/da
Priority to NZ333687A priority patent/NZ333687A/xx
Application filed by Gilead Sciences, Inc. filed Critical Gilead Sciences, Inc.
Priority to AT97936257T priority patent/ATE240339T1/de
Priority to AU38970/97A priority patent/AU713374B2/en
Priority to CA002261619A priority patent/CA2261619C/fr
Publication of WO1998004569A1 publication Critical patent/WO1998004569A1/fr
Priority to HK99105370A priority patent/HK1020964A1/xx
Priority to LU91178C priority patent/LU91178I2/fr
Priority to NL300202C priority patent/NL300202I1/nl
Priority to FR05C0032C priority patent/FR05C0032I2/fr
Priority to LU91433C priority patent/LU91433I2/fr
Priority to NL300344C priority patent/NL300344I1/nl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • C07F9/65616—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings containing the ring system having three or more than three double bonds between ring members or between ring members and non-ring members, e.g. purine or analogs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
    • C07F9/6509—Six-membered rings
    • C07F9/6512—Six-membered rings having the nitrogen atoms in positions 1 and 3

Definitions

  • the present invention relates to intermediates for phosphonomethoxy nucleotide analogs, in particular intermediates suitable for use in the efficient oral delivery of such analogs.
  • Z is independently -OC(R 2 )2 ⁇ C(0)X(R) a , an ester, an amidate or -H, but at least one Z is -OC(R 2 )2 ⁇ C(0)X(R) a ;
  • A is the residue of an antiviral phosphonomethoxy nucleotide analog
  • X is N or O
  • R 2 independently is -H, -C12 alkyl, C5- 2 aryl, C2- 2 alkenyl, C2- C12 alkynyl, C7-C12 alkenylaryl, C7-C12 alkynylaryl, or C6-C12 alkaryl, any one of which is unsubstituted or is substituted with 1 or 2 halo, cyano, azido, nitro or -OR 3 in which R 3 is -C12 alkyl, C2- 2 alkenyl, C2-C12 alkynyl or C5-C12 aryl;
  • R independently is -H, -C12 alkyl, C5-C12 aryl, C2-C12 alkenyl, C2- C12 alkynyl, C7- 2 alkyenylaryl, C7-C12 alkynylaryl, or C6-C12 alkaryl, any one of which is unsubstituted or is substituted with 1 or 2 halo, cyano, azido, nitro, -N(R 4 )2 or -OR 3 , where R 4 independently is -H or Ci-Cs alkyl, provided that at least one R is not H; and a is 1 when X is O, or 1 or 2 when X is N; with the proviso that when a is 2 and X is N, (a) two N-linked R groups can be taken together to form a carbocycle or oxygen-containing heterocycle, (b) one N-linked R additionally can be -OR 3 or (c) both N-linked R groups can be -H; and the salts,
  • B is guanin-9-yl, adenin-9-yl, 2,6-diaminopurin-9-yl, 2-aminopurin- 9-yl or their 1-deaza, 3-deaza, or 8-aza analogs, or B is cytosin-1-yl;
  • R is independently -H, C1-C12 alkyl, C5-C12 aryl, C2-C12 alkenyl, C2-C12 alkynyl, C7-C12 alkenylaryl, C7-C12 alkynylaryl, or C6-C12 alkaryl, any one of which is unsubstituted or is substituted with 1 or 2 halo, cyano, azido, nitro or -OR 3 in which R 3 is -C12 alkyl, C2- 2 alkenyl, C2-C12 alkynyl or C5- 2 aryl;
  • R 2 independently is hydrogen or C1-C6 alkyl
  • R 8 is hydrogen or -CHR 2 -0-C(0)-OR, or R 8 is joined with R 1 to form -CH2-; and the salts, hydrates, tautomers and solvates thereof.
  • Other embodiments comprise orally administering to a patient infected with virus or at risk for viral infection a therapeutically effective amount of a compound of formulas (la) or (1).
  • Other embodiments of this invention include a method for preparing a compound of formula (la) which comprises reacting the diacid of a phosphonomethoxy nucleotide analog with LC(R 2 )2 ⁇ C(0)X(R)a wherein L is a leaving group.
  • a method for preparing a compound of formula (1) comprises reacting a compound of formula (4)
  • NMP, DMF and DMPU mean, respectively, N- methylpyrrolidinone, dimethylformamide and N,N'-dimethylpropyleneurea.
  • Heterocycle means aromatic and nonaromatic ringed moieties.
  • Heterocyclic moieties typically comprise one ring or two fused rings, where the ring(s) is 5- or 6-membered and typically contains 1 or 2 noncarbon atoms such as oxygen, nitrogen or sulfur, usually oxygen or nitrogen.
  • Alkyl as used herein, unless stated to the contrary, is C1-C12 hydrocarbon containing 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 or 12 carbon atoms in the form of normal, secondary, tertiary or cyclic structures.
  • Examples are -CH3, -CH2CH3, -CH2CH2CH3, -CH(CH 3 )2, -CH2CH2CH2CH3, -CH CH(CH 3 )2, -CH(CH 3 )CH 2 CH 3 , -C(CH 3 )3, -CH2CH2CH2CH3 -CH(CH 3 )CH2CH 2 CH3, -CH(CH CH 3 )2, -C(CH 3 )2CH 2 CH 3 , -CH(CH 3 )CH(CH 3 ) 2 , -CH 2 CH 2 CH(CH 3 ) 2 , -CH2CH(CH 3 )CH2CH 3 , -CH 2 C(CH 3 ) 3 , -CH2CH2CH2CH2CH2CH3, -CH(CH 3 )CH2CH2CH2CH 3 , -CH(CH2CH 3 )(CH2CH2CH 3 ), -C(CH 3 ) 2 CH 2 CH2CH 3 , -CH(
  • -CH(CH 3 )CH CHCH 3
  • -CH(CH 3 )CH2CH CH2
  • -CH2CH C(CH 3 )2
  • Alkynyl as used herein, unless stated to the contrary, is C -C 1 2 hydrocarbon containing normal, secondary, tertiary or cyclic structures. Examples are -CCH, -CCCH3, -CH2CCH, -CCCH2CH3, -CH2CCCH3, -CH2CH2CCH, CH(CH3)CCH, -CCCH2CH2CH 3 , -CH2CCCH2CH 3 , -CH2CH2CCCH 3 and -CH2CH2CH2CCH.
  • Salt(s) include those derived by combination of appropriate anions such as inorganic or organic acids.
  • Suitable acids include those having sufficient acidity to form a stable salt, preferably acids of low toxicity.
  • Exemplary organic sulfonic acids include C 6 - 1 6 aryl sulfonic acids, C6-1 6 heteroaryl sulfonic acids and C 1 - 1 6 alkyl sulfonic acids such as phenyl, a-naphthyl, b-naphthyl, (S)-camphor, methyl, ethyl, n-propyl, f-propyl, n- butyl, s-butyl, / ' -butyl, f-butyl, pentyl and hexyl sulfonic acids.
  • Exemplary organic carboxylic acids include C1-16 alkyl, C ⁇ -i ⁇ ar yl carboxylic acids and C 4 -16 heteroaryl carboxylic acids such as acetic, glycolic, lactic, pyruvic, malonic, glutaric, tartaric, citric, fumaric, succinic, malic, maleic, hydroxymaleic, benzoic, hydroxybenzoic, phenylacetic, cinnamic, salicylic and 2-phenoxybenzoic. Salts also include the invention compound salts with one or more amino acids.
  • amino acids are suitable, especially the naturally-occurring amino acids found as protein components, although the amino acid typically is one bearing a side chain with a basic or acidic group, e.g., lysine, arginine or glutamic acid, or a neutral group such as glycine, serine, threonine, alanine, isoleucine, or leucine.
  • Salts are usually biologically compatible or pharmaceutically acceptable or non- toxic, particularly for mammalian cells. Salts that are biologically toxic are generally used with synthetic intermediates of invention compounds.
  • the salts of invention compounds may be crystalline or noncrystalline.
  • A is the residue of a phosphonomethoxy nucleotide analog.
  • A has the structure BQ wherein B is a purine or pyrimidine base or the aza and /or deaza analogs thereof and Q is a cyclic or acyclic aglycon. B is linked to Q through the purine 9 or pyrimidine 1 positions. Examples of these analogs can be found in U.S.
  • A will have the structure BCH2CH(CH 3 )- or BCH2CH2-.
  • a is an integer of 1 or 2. If X is N then a is 2 and one R is usually H and the other is not H. If X is O then a is 1.
  • B generally is guanin-9-yl, adenin-9-yl, 2,6-diaminopurin-9-yl, 2- aminopurin-9-yl or their 1-deaza, 3-deaza, or 8-aza analogs, or B is cytosin-1-yl. Ordinarily, B is adenin-9-yl or 2,6-diaminopurin-9-yl.
  • one Z optionally comprises an ester or an amidate. Suitable esters or amidates have been described, e.g., WO 95/07920.
  • esters are phenyl, benzyl, o-ethoxyphenyl, p-ethoxyphenyl, 2-pyridyl, 3-pyridyl, 4- pyridyl, N-ethylmorpholino, Ci-Cs O-alkyl and Ci-Cs NH-alkyl.
  • every compound of the invention will contain at least one -C(R 2 )2 ⁇ C(0)X(R) a moiety.
  • R 2 independently is -H, C1-C12 alkyl, C5- 2 aryl, C2-C12 alkenyl, C2-C12 alkynyl, C7-C12 alkenylaryl, C7-C12 alkynylaryl, or C6-C12 alkaryl, any one of which is unsubstituted or is substituted with 1 or 2 halo, cyano, azido, nitro or -OR 3 in which R 3 is C ⁇ -Ci2 alkyl, C2-C12 alkenyl, C2-C12 alkynyl or C5-C12 aryl.
  • R 2 is usually H or C1-C6 alkyl, and typically only one R 2 is other than H.
  • R 2 is H in both instances.
  • the carbon atom to which R 2 is bonded is capable of chiral substitution, in which case R 2 is in the (R), (S) or racemic configuration.
  • R 2 is other than H the compounds of this invention are chirally enriched or pure at this site. In general, however, manufacturing is somewhat less expensive if chirality at the R 2 carbon can be avoided.
  • R 2 is H when it is desired to help minimize the cost of synthesis.
  • X is O or N, typically O.
  • R independently is -H, C1- 2 alkyl, C5-C12 aryl, C2- 2 alkenyl, C2- C12 alkynyl, C7-C12 alkyenylaryl, C7-C12 alkynylaryl, or C6-C12 alkaryl, any one of which is unsubstituted or is substituted with 1 or 2 halo, cyano, azido, nitro, -N(R 4 )2 or -OR 3 , where R 4 independently is -H or Ci-Cs alkyl, provided that at least one R is not H.
  • R is C ⁇ -C6 secondary or normal alkyl which is unsubstituted or substituted with OR 3 .
  • R When X is N then a is 2. In the latter case one R is usually other than H. Alternatively, two N-linked R groups are joined to form a carbocycle or O- containing heterocycle, typically containing 3 to 5 carbon atoms in the ring.
  • R When R is unsaturated, but not aryl, the site of unsaturation is not critical and is in the Z or E configuration.
  • the alkenyl chains of naturally occurring unsaturated fatty acids would be suitable as R groups, for example.
  • R also includes cycloalkenyl or cycloalkynyl containing 1 or 2 unsaturated bonds, typically 1 unsaturated bond. When R is unsaturated, usually it is alkenyl or alkynyl without aryl substitution.
  • R is substituted with halo, cyano, azido, nitro or OR 3 , typically R will contain 1 of these substituents. If substituted with 2 of these substituents, they are same or different. Generally, substituents found on R are OR 3 .
  • An exemplary R group containing an OR 3 substituent is -CH2C(CH2 ⁇ CH3)(CH3)2-
  • R contains an aryl group
  • the aryl group generally is bonded directly to X or is linked to X by methylene or ethylene.
  • the aryl group contains 5 or 6 carbons. If substituted, the aryl moiety is substituted with halo or OR 3 in the ortho, meta or para positions, with R 3 in this instance being typically C1-C3.
  • Aryl groups containing 5 carbons are typically 2-, 3- or 4- pyridyl. In general, only one substituent group will be found on the aryl moiety if it is substituted at all.
  • Exemplary aromatic and nonaromatic heterocyclic groups as used herein includes by way of example and not limitation the heterocycles described in Paquette, Leo A.; “Principles of Modern Heterocyclic Chemistry” (W.A. Benjamin, New York, 1968), particularly Chapters 1, 3, 4, 6, 7, and 9; “The Chemistry of Heterocyclic Compounds, A series of Monographs” (John Wiley & Sons, New York, 1950 to present), in particular Volumes 13, 14, 16, 19, and 28; and "J. Am. Chem. Soc", 82:5566 (1960).
  • heterocycles include by way of example and not limitation pyridyl, thiazolyl, tetrahydrothiophenyl, sulfur oxidized tetrahydrothiophenyl, pyrimidinyl, furanyl, thienyl, pyrrolyl, pyrazolyl, imidazolyl, tetrazolyl, benzofuranyl, thianaphthalenyl, indolyl, indolenyl, quinolinyl, isoquinolinyl, benzimidazolyl, piperidinyl, 4-piperidonyl, pyrrolidinyl, 2-pyrrolidonyl, pyrrolinyl, tetrahydrofuranyl, tetrahydroquinolinyl, tetrahydroisoquinolinyl, decahydroquinolinyl, octahydroisoquinolinyl, azocinyl, triazinyl
  • carbon bonded heterocycles are bonded at position 2, 3, 4, 5, or 6 of a pyridine, position 3, 4, 5, or 6 of a pyridazine, position 2, 4, 5, or 6 of a pyrimidine, position 2, 3, 5, or 6 of a pyrazine, position 2, 3, 4, or 5 of a furan, tetrahydrofuran, thiofuran, thiophene, pyrrole or tetrahydropyrrole, position 2, 4, or 5 of an oxazole, imidazole or thiazole, position 3, 4, or 5 of an isoxazole, pyrazole, or isothiazole, position 2 or 3 of an aziridine, position 2, 3, or 4 of an azetidine, position 2, 3, 4, 5, 6, 7, or 8 of a quinoline or position 1, 3, 4, 5, 6, 7, or 8 of an isoquinoline.
  • carbon bonded heterocycles include 2-pyridyl, 3-pyridyl, 4-pyridyl, 5-pyridyl, 6- ⁇ yridyl, 3-pyridazinyl, 4- pyridazinyl, 5-pyridazinyl, 6-pyridazinyl, 2-pyrimidinyl, 4-pyrimidinyl, 5- pyrimidinyl, 6-pyrimidinyl, 2-pyrazinyl, 3-pyrazinyl, 5-pyrazinyl, 6- pyrazinyl, 2-thiazolyl, 4-thiazolyl, or 5-thiazolyl.
  • nitrogen bonded heterocycles are bonded at position 1 of an aziridine, azetidine, pyrrole, pyrrolidine, 2- pyrroline, 3-pyrroline, imidazole, imidazolidine, 2-imidazoline, 3- imidazoline, pyrazole, pyrazoline, 2-pyrazoline, 3-pyrazoline, piperidine, piperazine, indole, indoline, lH-indazole, position 2 of a isoindole, or isoindoline, position 4 of a morpholine, and position 9 of a carbazole, or b- carboline.
  • nitrogen bonded heterocycles include 1- aziridyl, 1-azetedyl, 1-pyrrolyl, 1-imidazolyl, 1-pyrazolyl, and 1-piperidinyl.
  • R includes the structure -C 2 -C6R 5 C 2 -C 6 where each C2-C independently is a 2, 3, 4, 5 or 6 carbon linear, branched or cyclic alkyl moiety, e.g., ethylene, ethyl, propylene, propyl, isopropylene, isopropyl, cyclohexyl, etc., and R 5 is -O- or -NR 6 - where R 6 is linear, branched or cyclic alkyl having 1, 2, 3, 4, 5 or 6 carbon atoms.
  • Embodiments include compounds where R 4 is -H or -CH3.
  • R includes the structure -C2-C12R 9 , where each C2-C 1 2 independently is a 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 or 12 carbon linear, branched or cyclic alkyl moiety, and R 9 is
  • N-morpholino N-piperidino, 2-pyridyl, 3-pyridyl or 4-pyridyl.
  • R also includes -C(CH 2 (X) 0 -iR 7 )3, -CH[C(CH 2 (X)o-iR 7 )3]2 and -CH 2 (C(X) 0- lR 7 )3, where R 7 is 1, 2, 3, 4, 5 or 6 carbon linear, branched or cyclic alkyl or R 7 is 5 or 6 carbon aryl.
  • R 7 is 1, 2, 3, 4, 5 or 6 carbon linear, branched or cyclic alkyl or R 7 is 5 or 6 carbon aryl.
  • one or two X are typically present, usually 1, X is usually oxygen and R 7 is typically methyl, ethyl, isopropyl, propyl or butyl, usually methyl.
  • R usually is phenyl, methyl, ethyl, 1-propyl, 2-propyl, n-butyl, i-butyl, t- butyl, pentyl or 3-pentyl.
  • R ⁇ is usually H or methyl. If R! and R 8 are joined to form methylene, B typically is cytosin-1-yl.
  • R 3 is C1-C12 alkyl, but typically is -C6 alkyl.
  • Compounds of structure (1) typically are those in which B is adenin-9- yl, R 1 is methyl or H, R 8 is -CHR 2 -0-C(0)-OR and R, R 2 and R 3 are as set forth above.
  • the compounds of this invention are optionally enriched or resolved at the carbon atom chiral center linked to R 1 in accordance with prior findings associating optimal antiviral activity with the configuration at this site.
  • R ⁇ is methyl the compounds will be in (R) configuration at this center and will be substantially free of the (S) enantiomer.
  • Exemplary embodiments include the compounds named in Table B. Each compound in Table B is depicted as a compound having the formula (8)
  • Exemplary embodiments include the following numbered groups of compounds. 1
  • Table B having only one carbonate moiety and a hydroxyl group linked to the phosphorus atom in place of the second carbonate moiety, i.e., B-CH 2 -CHRl-0-CH 2 -P(0)(OH)-0-CHR 2 -0-C(0)-OR.
  • group 1 compound named 1.4.1.1 in Table B has the structure: adenin-9-yl-CH 2 -CH(CH3)-0-CH2-P(0)(OH)-0-CH2-0-C(0)-OCH(CH 3 )2.
  • the group 3 compound defined in Table A and named 1.4.1.1 in compound group 1 has the structure: l-deazaadenin-9-yl-CH 2 -CH(CH 3 )-0-CH2-P(0)(OH)-0-CH 2 -0-C(0)-OCH(CH 3 )2.
  • 5 Compounds named in Table B and compounds named by compound groups 1 and 2 where each purine base listed in Table A is the 8-aza analog, e.g., 8-azaadenin-9-yl.
  • 6 Compounds named in Table B and compounds named by compound groups 1-5 where R moieties 1-25 listed in Table A are replaced with the following groups:
  • the group 6 compound defined in Table A and named 1.16.1.1 in Table B has the structure: adenin-9-yl-CH 2 -CH(CH 3 )-0-CH2-P(0)(-0-CH 2 -0-C(0)-0-cyclohexyl)2.
  • the group 6 compound defined in Table A and named 1.16.1.1 in compound group 1 has the structure: adenin-9-yl-CH 2 -CH(CH 3 )-0-CH 2 -P(0)(OH)-0-CH 2 -0-C(0)-0-cyclohexyl.
  • the group 6 compound defined in Table A and named 1.16.1.1 in compound group 3 has the structure:
  • the group 15B compound defined in Table A and named 1.1.1.1 in compound group 1, as named under group 8, has the structure: adenin-9-yl-CH 2 -CH(CH 3 )-0-CH 2 -P(0)(OH)-0-CH 2 -0-C(0)-0-(CH 2 ) 2 N(CH 3 )2.
  • the group 15B compound defined in Table A and named 1.16.1.1 in compound group 3, as named under group 8, has the structure: 3-deazaadenin-9-yl-CH 2 -CH(CH 3 )-0-CH 2 -P(0)(-0-CH 2 -0-C(0)-0- (CH 2 ) 2 N(CH 3 ) 2 ) 2 .
  • R 9 is N-morpholino, in moieties 11-20, R 9 is 2-pyridyl and in moieties 21-25, R 9 is 3-pyridyl.
  • the group 18 A compound defined in Table A and named 1.4.2.3 in Table B has the structure: adenin-9-yl-CH2-CH2-0-CH(CH 3 )-P(0)(-0-C(C 2 H5)(CH3)-0-C(0)-0-CH(CH3)2)2.
  • the group 18 A compound defined in Table A and named 1.4.1.1 in compound group 1 has the structure: adenin-9-yl-CH 2 -CH(CH3)-0-CH2-P(0)(OH)-0-CH(CH 3 )-0-C(0)-0-CH(CH 3 ) 2 .
  • the group 18 A compound defined in Table A and named 1.1.1.1 in compound group 3, as named under compound group 8, has the structure: 3-deazaadenin-9-yl-CH2-CH(CH 3 )-0-CH 2 -P(0)(-0-CH(CH 3 )-0-C(0)-0-
  • the group 19 compound defined in Table A and named 1.4.1.1 in Table B has the structure: adenin-9-yl-CH2-CH(CH 3 )-0-CH(CH 3 )-P(0)(-0-CH2-0-C(0)-N-CH(CH 3 )2)2.
  • the group 19 compound defined in Table A and named 1.4.1.1 in compound group 1 has the structure: adenin-9-yl-CH2-CH(CH 3 )-0-CH2-P(0)(OH)-0-CH2-0-C(0)-N-CH(CH 3 )2.
  • the group 19 compound defined in Table A and named 1.1.1.1 in compound group 3, as named under compound group 8, has the structure: 3-deazaaden -9-yl-CH 2 -CH(CH 3 )-0-CH 2 -P(0)(-0-CH 2 -0-C(0)-N-
  • the compounds of this invention are, to varying degrees, chemically stable. It is preferable that the compounds be chemically stable in order to ensure an adequate shelf-life and proper biodistribution upon oral administration.
  • embodiments are selected that have a t 1/2 at pH 7.4 of greater than 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 or 12 hours and preferably in addition possess a 1 1/2 at pH 2.0 of greater than 1, 10 or 100 hours.
  • the t-butyl carbonate found in Table 1 has a 1 1 /2 that is less stable than these parameters and therefor is not preferred.
  • the optimal compounds of this invention should have bioavailability in beagle dogs (as set forth in more detail below) that exceeds about 20%, preferably, about 30%.
  • the carbamates and carbonates of this invention are prepared from the diacids of the phosphonomethoxy nucleotide analogs and the synthon LCH(R 2 )OC(0)X(R) a .
  • L is a leaving group such as Cl, although it will be appreciated that any of the conventional leaving groups used in organic chemistry in nucleophilic substitution reactions can be successfully employed in place of chloro.
  • leaving groups include halides, such as Cl, Br and I, and sulfonic acid esters such as methane, benzene or toluene sulfonic acid esters.
  • the synthon is prepared by reacting LCH(R 2 )OC(0)L with HOR for preparation of the carbonate synthon or HNR2 for the preparation of the carbamate synthon.
  • the synthon is then reacted with the nucleotide analog of choice, typically PMPA, to form the desired carbamate or carbonate adducts.
  • the carbamates are prepared by reacting the synthon with the nucleotide analog under typical conditions of nucleophilic attack, for example in Et 3 N/DMF at room temperature.
  • the carbonates are formed by reacting the appropriate synthon with the nucleotide analog in the presence of an organic base, typically an amine base.
  • masked leaving groups such as thioethers, which may be activated by, for example, oxidation, and coupled directly to the phosphonic acid moiety may be used.
  • Intermediates may be made with other leaving groups in this way, for example diphenylphosphinic acids, and others known in the chemistry of formacetals and glycosylation.
  • N O- dialkylhydroxylamines are known in the literature, and may be prepared by alkylation of hydroxylamine, or by reductive amination of aldehydes or ketones with alkyl hydroxylamines.
  • the dialkylhydroxylamines may be acylated with the appropriately substituted haloalkyl chloroformate under conditions analagous to those used to prepare the unsubstituted chloromethyl carbamates.
  • Phosphonates may then be alkylated with the haloalkyl, O-alkyl carbamates to give the prodrugs under conditions used for the carbonates and carbamates. Leaving groups other than chloride may of course be used throughout.
  • the carbonate compounds of this invention are prepared by reacting L-CHR 2 -0-C(0)-OR with (4) to yield a compound of formula (1).
  • the reaction typically proceeds in two concurrent steps in which the monoester forms first, and then the diester as the reaction proceeds longer. In this situation monoester is not typically isolated as an intermediate. In order to make a diester that contains different carbonate or carbamate functionalities the monoester intermediate is recovered from the early reaction and the reaction is then completed with for example a second L-CHR 2 -0-C(0)-OR reagent, thereby resulting in substitution with a second ester different from the first.
  • the reaction is conducted in the presence of an organic base in an organic solvent at a reaction temperature of about 4-100° for about 4-72 hours.
  • Exemplary suitable organic bases include triethylamine or Hunig's base.
  • Exemplary suitable organic solvents include DMF, DMPU, or NMP.
  • the monoester or diester products are purified by standard methods including flash column chromatography or salting out.
  • Suitable salts for purification and /or formulation will final product include the sulfuric acid, phosphoric acid, lactic acid, fumaric or citric acid salts or complexes of the diester or monoester compounds of structures (1) or (la).
  • the compounds of this invention are useful in the treatment or prophylaxis of one or more viral infections in man or animals, including infections caused by DNA viruses, RNA viruses, herpesviruses (CMV, HSV 1, HSV 2, VZV, and the like), retroviruses, hepadnaviruses, (e.g. HBV), papillomavirus, hantavirus, adenoviruses and HIV.
  • Other infections to be treated with the compounds herein include MSV, RSV, SIV, FIV, MuLV, and other retroviral infections of rodents and other animals.
  • the prior art describes the antiviral specificity of the nucleotide analogs, and the parental drug specificity is shared by the compounds of this invention.
  • Dosages, viral targets, and suitable administration routes to best attack the site of infection are well known in the art for the parental drugs. Determination of proper doses is a straightforward matter for the clinician, taking into account the molecular weight of the compounds of this invention and, when adminstering them orally, their bioavailability in animals or as deduced in clinical trials with humans.
  • Oral dosages of the compounds of this invention in humans for antiviral therapy will range about from 0.5 to 60 mg/Kg/day, usually about from 1 to 30 mg/Kg/day and typically about from 1.5 to 10 mg/Kg/day.
  • the compounds of this invention also are useful as intermediates in the preparation of detectable labels for oligonucleotide probes.
  • the compounds are hydrolyzed to yield the diacid, diphosphorylated and incorporated into an oligonucleotide by conventional enzymatic or chemical means.
  • the incorporated base from the compound of the invention will be capable of participating in base pairing and thus will not interfere substantially with the binding of the oligonucleotide to its complementary sequence (E. De Clercq Rev. Med. Virol. 3:85-96 1993). However, if it does interfere with binding of the oligonucleotide containing the analog to the complementary sequence, the compound of the invention optionally is incorporated into the oligonucleotide as the 3' terminal base, an innocuous position and a conventional site for oligonucleotide labeling.
  • the aglycon donated by the nucleotide analog that is incorporated into the oligonucleotide is detected by any means, such as NMR or by binding to antibodies specific for the nucleotide analog.
  • compositions of the invention and their pharmaceutically, i.e. physiologically, acceptable salts are administered by any route appropriate to the condition to be treated, suitable routes including oral, rectal, nasal, topical (including ocular, buccal and sublingual), vaginal and parenteral (including subcutaneous, intramuscular, intravenous, intradermal, intrathecal and epidural).
  • suitable routes including oral, rectal, nasal, topical (including ocular, buccal and sublingual), vaginal and parenteral (including subcutaneous, intramuscular, intravenous, intradermal, intrathecal and epidural).
  • the compounds of this invention are administered orally, but if an embodiment is not sufficiently orally bioavailable it can be administered by any of the other routes noted above.
  • the formulations of the present invention comprise at least one active ingredient, as above defined, together with one or more acceptable carriers and optionally other therapeutic ingredients.
  • the carrier(s) must be "acceptable” in the sense of being compatible with the other ingredients of the formulation and not deleterious to the patient.
  • the formulations include those suitable for topical or systemic administration, including oral, rectal, nasal, buccal, sublingual, vaginal or parenteral (including subcutaneous, intramuscular, intravenous, intradermal, intrathecal and epidural) administration.
  • the formulations are in unit dosage form and are prepared by any of the methods well known in the art of pharmacy.
  • Such methods include the step of bringing into association the active ingredient with the carrier which constitutes one or more accessory ingredients.
  • the formulations are prepared by uniformly and intimately bringing into association the active ingredient with liquid carriers or finely divided solid carriers or both, and then, if necessary, shaping the product.
  • Formulations of the present invention suitable for oral administration may be presented as discrete units such as capsules, cachets or tablets each containing a predetermined amount of the active ingredient; as a powder or granules; as solution or a suspension in an aqueous liquid or a non-aqueous liquid; or as an oil-in-water liquid emulsion or a water-in-oil liquid emulsion.
  • the active ingredient may also be presented as a bolus, electuary or paste.
  • a tablet may be made by compression or molding, optionally with one or more accessory ingredients.
  • Compressed tablets may be prepared by compressing in a suitable machine the active ingredient in a free-flowing form such as a powder or granules, optionally mixed with a binder, lubricant, inert diluent, preservative, surface active or dispersing agent.
  • Molded tablets may be made by moulding in a suitable machine a mixture of the powdered compound moistened with an inert liquid diluent.
  • the tablets may optionally be coated or scored and may be formulated so as to provide slow or controlled release of the active ingredient therein.
  • the formulations are preferably applied as a topical ointment or cream containing the active ingredient(s) in an amount of, for example, 0.01 to 10% (including active ingredient(s) in a range between 0.1% and 5% in increments of 0.1% w/w such as 0.6% w/w, 0.7% w/w, etc), preferably 0.2 to 3% w/w and most preferably 0.5 to 2% w/w.
  • the active ingredients may be employed with either a paraffinic or a water-miscible ointment base.
  • the active ingredients may be formulated in a cream with an oil-in-water cream base.
  • the aqueous phase of the cream base may include, for example, at least 30% w/w of a polyhydric alcohol, i.e. an alcohol having two or more hydroxyl groups such as propylene glycol, butane 1,3-diol, mannitol, sorbitol, glycerol and polyethylene glycol (including PEG 400) and mixtures thereof.
  • the topical formulations may desirably include a compound which enhances absorption or penetration of the active ingredient through the skin or other affected areas. Examples of such dermal penetration enhancers include dimethyl sulphoxide and related analogs.
  • the oily phase of the emulsions of this invention may be constituted from known ingredients in a known manner.
  • the phase may comprise merely an emulsifier (otherwise known as an emulgent), it desirably comprises a mixture of at least one emulsifier with a fat or an oil or with both a fat and an oil.
  • a hydrophilic emulsifier is included together with a lipophilic emulsifier which acts as a stabilizer. It is also preferred to include both an oil and a fat.
  • the emulsifier(s) with or without stabilizer(s) make up the emulsifying wax, and the wax together with the oil and fat make up the emulsifying ointment base which forms the oily dispersed phase of the cream formulations.
  • Emulgents and emulsion stabilizers suitable for use in the formulation of the present invention include Tween® 60, Span® 80, cetostearyl alcohol, benzyl alcohol, myristyl alcohol, glyceryl mono-stearate and sodium lauryl sulfate.
  • the choice of suitable oils or fats for the formulation is based on achieving the desired cosmetic properties.
  • the cream should preferably be a non-greasy, non-staining and washable product with suitable consistency to avoid leakage from tubes or other containers.
  • Straight or branched chain, mono- or dibasic alkyl esters such as di-isoadipate, isocetyl stearate, propylene glycol diester of coconut fatty acids, isopropyl myristate, decyl oleate, isopropyl palmitate, butyl stearate, 2-ethylhexyl palmitate or a blend of branched chain esters known as Crodamol CAP may be used, the last three being preferred esters.
  • Crodamol CAP may be used, the last three being preferred esters.
  • high melting point lipids such as white soft paraffin and /or liquid paraffin or other mineral oils can be used.
  • Formulations suitable for topical administration to the eye also include eye drops wherein the active ingredient is dissolved or suspended in a suitable carrier, especially an aqueous solvent for the active ingredient.
  • a suitable carrier especially an aqueous solvent for the active ingredient.
  • the active ingredient is suitably present in such formulations in a concentration of 0.01 to 20%, in some embodiments 0.1 to 10%, and in others about 1.0% w/w.
  • Formulations suitable for topical administration in the mouth include lozenges comprising the active ingredient in a flavored basis, usually sucrose and acacia or tragacanth; pastilles comprising the active ingredient in an inert basis such as gelatin and glycerin, or sucrose and acacia; and mouthwashes comprising the active ingredient in a suitable liquid carrier.
  • Formulations for rectal administration may be presented as a suppository with a suitable base comprising for example cocoa butter or a salicylate.
  • Formulations suitable for nasal or inhalational administration wherein the carrier is a solid include a powder having a particle size for example in the range 1 to 500 microns (including particle sizes in a range between 20 and 500 microns in increments of 5 microns such as 30 microns, 35 microns, etc).
  • Suitable formulations wherein the carrier is a liquid, for administration as for example a nasal spray or as nasal drops include aqueous or oily solutions of the active ingredient.
  • Formulations suitable for aerosol administration may be prepared according to conventional methods and may be delivered with other therapeutic agents. Inhalational therapy is readily administered by metered dose inhalers.
  • Formulations suitable for vaginal administration may be presented as pessaries, tampons, creams, gels, pastes, foams or spray formulations containing in addition to the active ingredient such carriers as are known in the art to be appropriate.
  • Formulations suitable for parenteral administration are sterile and include aqueous and non-aqueous injection solutions which may contain anti-oxidants, buffers, bacteriostats and solutes which render the formulation isotonic with the blood of the intended recipient; and aqueous and non- aqueous sterile suspensions which may include suspending agents and thickening agents.
  • the formulations may be presented in unit-dose or multi- dose containers, for example sealed ampoules and vials with elastomeric stoppers, and may be stored in a freeze-dried (lyophilized) condition requiring only the addition of the sterile liquid carrier, for example water for injections, immediately prior to use.
  • sterile liquid carrier for example water for injections
  • Extemporaneous injection solutions and suspensions may be prepared from sterile powders, granules and tablets of the kind previously described.
  • Preferred unit dosage formulations are those containing a daily dose or unit daily sub-dose, as recited above, or an appropriate fraction thereof, of an active ingredient.
  • formulations of this invention may include other agents conventional in the art having regard to the type of formulation in question, for example those suitable for oral administration may include flavoring agents.
  • the present invention further provides veterinary compositions comprising at least one active ingredient as above defined together with a veterinary carrier therefor.
  • Veterinary carriers are materials useful for the purpose of administering the composition to cats, dogs, horses, rabbits and other animals and may be solid, liquid or gaseous materials which are otherwise inert or acceptable in the veterinary art and are compatible with the active ingredient. These veterinary compositions may be administered orally, parenterally or by any other desired route.
  • Compounds of the invention can be used to provide controlled release pharmaceutical formulations containing a matrix or absorbent material and as active ingredient one or more compounds of the invention in which the release of the active ingredient can be controlled and regulated to allow less frequent dosing or to improve the pharmacokinetic or toxicity profile of the compound.
  • Controlled release formulations adapted for oral administration in which discrete units comprising one or more compounds of the invention can be prepared according to conventional methods.
  • Process Summary PMPA is prepared as follows: (S)-Glycidol is reduced to (R)-l,2- propanediol by catalytic hydrogenation, which is then reacted with diethyl carbonate to afford (_ .)-l,2-propylene carbonate.
  • the carbonate is reacted with adenine and catalytic amounts of a base such as sodium hydroxide to give (R)- 9-[2-(diethylphosphonomethoxy)propyl]adenine which, without isolation, is reacted with lithium alkoxide (alkyl containing 1, 2, 3, 4, 5 or 6 carbon atoms, e.g., ⁇ -hexoxide, ⁇ -pentoxide, n-butoxide, /-butoxide, ,-butoxide, n-propoxide, -propoxide, ethoxide, methoxide) and diethyl p-toluenesulfonyl- oxymethylphosphonate (prepared by reacting diethyl phosphite and paraformaldehyde, and tosylating the product in situ).
  • a base such as sodium hydroxide
  • the process uses a small amount of a base such as NaOH at step 1, which increases the reaction rate about 10-fold compared to the same reaction lacking the base.
  • Step 1 also uses hydrogen gas instead of using a reagent such as HC ⁇ 2 NH to generate hydrogen in situ.
  • the process uses lithium alkoxide at step 4b, which is mildly exothermic on addition to the reaction mixture.
  • the use of a highly reactive base such as NaH results in an exothermic reaction that generates hydrogen gas in a reaction is difficult to control.
  • the use of NaH thus requires more labor and care to use than lithium alkoxide.
  • Lithium alkoxide bases also give a product that has an improved by-product profile compared to that obtained using NaH, e.g., lower amounts of starting material or overalkylated products usually result from the use of lithium alkoxide.
  • the scale of the following method is proportionately reduced or increased if desired.
  • the scheme and process steps depict synthesis of (R)- PMPA.
  • the scheme and process steps depict synthesis of (R)-PMPA and (R)-bis(PO PMPA.
  • Step 1 (R)-1.2-Propanediol: (S)-Glycidol (1.0 kg, 13.5 moles) is added to a reactor containing (i) an inert, e.g., nitrogen, atmosphere and (ii) a stirred suspension of 5% palladium on activated carbon (50% wet) catalyst (100 g) in denatured ethyl alcohol containing 2 mole% sodium hydroxide (7.85 kg EtOH and 54 g of 16.7% NaOH solution). The contents of the inerted reactor containing catalyst and the ethanol solution is usually cooled to about 0°C (usually about -5 to 5°C) before the (S)-glycidol is added.
  • Hydrogen gas at no more than 20 psi is then introduced to the inerted reaction vessel containing reactants at a temperature of no more than 25°C.
  • the mixture is agitated for approximately 4-5 hours, until hydrogen consumption stops. Reaction completion is monitored by TLC (trace or no (S)-glycidol remaining).
  • the mixture is then filtered e.g., diatomaceous earth (about 150 g), to remove solids and the filtrate is concentrated in vacuo at no more than 50°C, until volatile collection stops or is very slow, to obtain an oil containing the crude product.
  • the crude product is used directly in the next step.
  • Title compound yield is about 100%.
  • Step 2 Diethyl carbonate (1.78 kg, 15.1 moles) and sodium ethoxide in denatured ethyl alcohol (210 g of 21% w/w sodium ethoxide in ethanol) are added to (R)-l,2-propanediol (1.0 kg theoretical based on the quantity of (S)-glycidol used in step 1 above), and the solution is heated to 80 to 150°C to distill off the ethanol. If necessary to achieve reaction completion, additional diethyl carbonate (0.16 kg) is added to the reaction mixture, followed by distillation to remove ethanol.
  • Reaction completion is monitored by TLC showing a trace or no detectable (R)-l,2- propanediol.
  • the residue is fractionally distilled at 120°C and 10-17 mm Hg, to yield the title compound as a colorless liquid.
  • the product purity is typically 96% or greater purity by GC analysis.
  • Step 3 Diethyl p-toluenesulfonyloxymethylphosphonate: In a reactor containing an inert atmosphere, e.g., nitrogen, a mixture of diethyl phosphite (0.80 kg), paraformaldehyde (0.22 kg), and triethylamine (0.06 kg) in toluene (0.11 kg) is heated at 87°C for about 2 hours, then refluxed for about 1 hour, until the reaction is complete as monitored by TLC showing a trace or no detectable diethyl phosphite. During the reaction, the inert atmosphere is maintained. Toluene is necessary to moderate the reaction, which may otherwise explode.
  • an inert atmosphere e.g., nitrogen
  • Reaction completion is optionally confirmed by H NMR (diethyl phosphite peak at ⁇ 8.4-8.6 ppm no longer detected).
  • the solution is cooled to about 1°C (typically about -2 to 4°C) and p-toluenesulfonyl chloride (1.0 kg) is added and then triethylamine (0.82 kg) at about 5°C is slowly added (exothermic addition) while maintaining the temperature at no more than about 10°C (typically 0 to 10°C).
  • the resulting mixture is warmed to 22°C and stirred for at least about 5 hours (typically about 4.5 to 6.0 hours), until the reaction is complete as shown by TLC (trace or no p-toluenesulfonyl chloride detectable) and optionally confirmed by H NMR (p-toluenesulfonyl chloride doublet at ⁇ 7.9 ppm no longer detected).
  • the solids are removed by filtration and washed with toluene (0.34 kg).
  • the combined washings and filtrate are washed either twice with water (1.15 kg per wash), or optionally with a sequence of water (1.15 kg), 5% aqueous sodium carbonate (3.38 kg), and then twice with water (1.15 kg).
  • the reactor contents are briefly agitated, allowed to settle and the lower aqueous layer is then discarded. If the reaction results in an emulsion, brine (0.23 kg of water containing 0.08 kg NaCl) may be added to the first organic/water mixture, followed by agitating the reactor contents, allowing the solids to settle, discarding the lower aqueous layer, adding 1.15 kg water, agitating, allowing solids to settle and again discarding the lower aqueous layer.
  • brine (0.23 kg of water containing 0.08 kg NaCl) may be added to the first organic/water mixture, followed by agitating the reactor contents, allowing the solids to settle, discarding the lower aqueous layer, adding 1.15 kg water, agitating, allowing solids to settle and again discarding the lower aqueous layer.
  • the organic phase is distilled in vacuo at no more than 50°C (to LOD at 110°C of no more than 10% and water content, by KF titration, no more than 0.3%), affording a yield of about 60-70% of the title compound as an oil of about 85-95% purity, exclusive of toluene.
  • Step 4 (R)-9-f2-(Diethylphosphonomethoxy)propyIladenine;
  • a mixture of adenine 1.0 kg
  • sodium hydroxide (11.8 g)
  • (R)-l,2-propylene carbonate (0.83 kg)
  • N,N- dimethylformamide 6.5 kg
  • the resulting mixture is cooled to about 25°C, typically about 20-30°C, and contains the stage I intermediate, (R)-9-(2- hydroxypropyl)adenine, which may precipitate out at this point.
  • lithium f-butoxide 3.62 kg
  • 2.0 M in tetrahydrofuran is added to the stage I intermediate, to produce the lithium salt of (R)-9-(2- hydroxypropyl)adenine in a mildly exothermic addition.
  • the slurry is treated with diethyl p-toluenesulfonyloxymethylphosphonate (1.19 kg) and the mixture is heated to a temperature of about 32°C, typically about 30-45°C, and is stirred for at least about 2 hours (typically about 2-3 hours) during which time the mixture becomes homogeneous. More diethyl p- toluenesulfonyloxymethylphosphonate (1.43 kg) is added and the mixture is stirred at a temperature of about 32°C (typically about 30-45°C) for at least about 2 hours (typically about 2-3 hours).
  • reaction mixture is maintained at a temperature of about 32°C for at least about 2 hours to achieve reaction completion.
  • the mixture is then cooled to about 25°C (typically about 20-40°C) and glacial acetic acid (0.5 kg) is then added.
  • the resulting mixture is concentrated in vacuo at a final maximum mixture temperature of about 80°C under about 29 in Hg vacuum.
  • the residue is cooled to about 50°C (typically about 40-60°C) and water (1.8 kg) is added and the reaction is rinsed forward with additional water (1.8 kg).
  • the solution is continuously extracted with dichloromethane (about 35 kg) for 12-48 hours with periodic additions of glacial acetic acid (0.2 kg) to the aqueous phase after about 5 hours and after about 10 hours of continuous extraction time. Extraction completion is optionally confirmed by area normalized HPLC as shown by no more than about 7% of (R)-9-[2- (diethylphosphonomethoxy)propyl]adenine remaining in the aqueous phase.
  • the combined dichloromethane extracts are concentrated initially at atmospheric pressure then in vacuo at an extract temperature of no more than about 80°C to give the title compound as a viscous orange oil.
  • the title compound yield is about 40-45% by weight normalized HPLC and its purity is typically 60-65% by area normalized HPLC.
  • the actual weight of the title compound after concentration is approximately 1.6 times the theoretical weight (or 3.8 times the expected yield). The additional observed weight is attributed to impurities and /or solvents remaining after the continuous extraction and concentration.
  • Step 5 (R)-9-[2-(Phosphonomethoxy)propylladenine, crude: Bromotrimethylsilane (1.56 kg) is added to a reactor containing a mixture of crude (R)-9-[2-(diethylphosphonomethoxy)propyl]adenine (1.0 kg calculated based on adenine input from step 4 above) and acetonitrile (0.9 kg) with cooling to maintain a temperature no higher than about 50°C.
  • the lines are rinsed forward with acetonitrile (0.3 kg) and the mixture is refluxed at about 60-75 °C for about 2-4 hours with moderate agitation to avoid splashing the reactor contents.
  • Reaction completion is monitored by area normalized HPLC showing no more than about 3% total of monoethyl PMPA and diethyl PMPA remaining. If the reaction is incomplete, additional bromotrimethylsilane (0.04 kg) is charged into the reactor and the reaction is refluxed for at least about 1 hour with moderate agitation. The volatiles are removed by distillation at no higher than about 70°C initially at atmospheric pressure and then in vacuo (about 24-27 in Hg) at no higher than about 70°C. The reactor is then cooled to about 20°C (typically about 15-25°C) and water (1.9 kg) is added (exothermic addition) to the residue with the temperature maintained at no higher than about 50°C.
  • the mixture is cooled to 20°C and washed with dichloromethane (1.7 kg) by agitating for about 30 minutes.
  • the isolated aqueous phase is then filtered through a 1 ⁇ m cartridge filter, diluted with water (3.2 kg), heated to about 40°C (typically about 35-50°C) and adjusted to pH about 1.1 (typically about 0.9-1.3) with aqueous sodium hydroxide (about 0.15 kg NaOH as a 50% solution) while the temperature is maintained at about 45°C.
  • PMPA seed crystals are added to the mixture and the pH is adjusted to about 2.8 (typically about 2.6-3.0) with a 50% aqueous sodium hydroxide solution (about 0.15 kg NaOH required) while the temperature is maintained at about 45°C (typically about 35-50° C).
  • the solution is cooled to about 22°C (typically about 15-25°C) over about 3-20 hours with slow to moderate agitation that avoids splashing the contents, during which time the product should precipitate, beginning at about 35°C.
  • the pH of the slurry is adjusted to about 3.2 (typically about 3.1-3.3), usually using 50% aqueous sodium hydroxide or concentrated hydrochloric acid, if necessary.
  • the slurry is cooled to approximately 5°C, typically about 0-10°C, and slowly agitated for at least about 3 hours in that temperature range.
  • the solids are collected by filtration, washed sequentially with cold water (0.35 kg) and acetone (0.3 kg) giving crude PMPA as a damp solid typically of about 97% purity.
  • the product is heated to about 50°C and dried in vacuo to a water content of less than 10%.
  • the quantity of diethyl PMPA is calculated from the quantity of adenine used in the preceding step of the synthesis (assuming 100% yield) and not from the net weight of the crude diethyl PMPA, which may contain other compounds.
  • Step 6 (R)-9-f2-(Phosphonomethoxy)propylladenine. pure: A suspension of the crude PMPA (1.00 kg corrected for water content) (Step 5 product) in water is heated to about 100°C (typically about 95-110°C) with moderate to high agitation until all solids dissolve, and the resulting solution is clarified by filtration while hot, rinsing forward using additional hot water (1 kg, about 95-110'C). The filtrate is heated to 100°C prior to cooling, first to about 30°C (typically about 20-25°C) over about 3-5 hours with slow agitation, then cooling is continued to about 10°C (typically about 5-15°C).
  • the solids are collected by filtration and washed sequentially with cold water (1.5 kg, about 0-10°C) and then acetone (1 kg).
  • the wet cake is dried in vacuo at about 50 °C (typically about 40-60°C) to a water content of about 5.9% (typically about 3.9-7.9%), affording pure PMPA monohydrate.
  • the product purity is typically 98% or greater by both area normalized and weight normalized HPLC. If the chemical purity is unsatisfactory, the product may be repurified by a repeat of this step.
  • Preparation C PMPA (0.50 g) was recrystallized from approximately 7.5 mL boiling H 2 0 (15:1 wt. ratio). Upon cooling to room temperature, the PMPA was filtered on a coarse frit fit with TyvekTM. The filter cake was rinsed with ice-cold H 2 0 and acetone then sucked to dryness to afford a fluffy white solid (Preparation D). The filtrate was also concentrated to afford a white solid (Preparation E).
  • Step 7 Bis(POC)PMPA fumarate: In a reactor with an inert atmosphere, e.g., nitrogen, a mixture of l-methyl-2-pyrrolidinone (4.12 kg), PMPA monohydrate (1.00 kg), triethylamine (0.996 kg), are agitated for about 15-45 min., typically about 30 min, and then chloromethyl-2-propyl carbonate (2.50 kg) is added and the mixture is heated to about 55-65°C, typically about 60°C and agitated without splashing the contents for about 3-6 hours, typically about 4 hours, until the reaction is complete, as optionally indicated by HPLC (no more than 15% mono(POC)PMPA present).
  • an inert atmosphere e.g., nitrogen
  • the mixture is diluted with isopropyl acetate (10.72 kg), cooled to about 15-30°C, typically about 25°C, as rapidly as possible, and while holding the reactor contents at a of about 15- 30°C, typically at about 25°C, the mixture is agitated for about 20-60 minutes, typically about 30 minutes.
  • the solids are removed by filtration and washed with isopropyl acetate (4.44 kg).
  • the combined organic phases at about 15- 30°C, typically about 25°C, are extracted twice with water (3.28 kg) using moderate agitation for about 1-10 min. to avoid forming an emulsion followed by allowing the phases to separate.
  • the combined aqueous phases are back-extracted twice with isopropyl acetate (3.56 kg) (about 15-30°C, typically about 25°C). All organic phases are combined and washed with water (2.20 kg) (about 15-30°C, typically about 25°C) using moderate agitation for about 1-10 min. to avoid forming an emulsion, then the combined organic phases, which are at about 25-43°C, but at no more than 45°C, are concentrated in vacuo (about 26.5-28" Hg) to approximately 30% of the original volume (about 10-12 L/kg PMPA monohydrate).
  • the concentration of the organic phase is resumed at about 20-38°C, but no higher than 40°C under a vacuum (about 28" Hg) until a pale yellow oil remains.
  • the oil is dissolved in a warmed solution (about 45-55° C, typically about 50°C) of fumaric acid (0.38 kg) in 2-propanol (6.24 kg) with vigorous agitation until solids dissolve, about 0.5-2.0 hours.
  • the warm solution is then optionally filtered using an in-line 1 ⁇ m filter while minimizing cooling of the solution.
  • the filtrate at about 34-50°C, typically at about 40°C, is agitated using the minimum agitation needed to obtain a homogenous solution.
  • the resulting solution is cooled to about 30-33°C, typically about 32°C, over about 30 minutes using minimal agitation, optionally seeded with a small quantity of bis(POC)PMPA fumarate (about 100 mg), and cooled to about 12-18°C, typically about 15°C, over about 1-2 hours, typically over about 1 hour. Seed crystals may not be needed if crystal formation begins before seed crystals are added. Crystals may form over a range of about 12-33°C as the solution is cooled. Crystallization will occur at lower temperatures if the solution is further chilled, e.g., to about -10° to about 11°C. Agitation is discontinued when crystal formation begins. The mixture is allowed to stand at about 15°C for at least about 12 hours, typically about 12-30 hours.
  • Butyl chloromethyl carbonate A solution of butyl alcohol (50 mmol) and chloromethyl chloroformate (4.5 mL, 50 mmol) in diethyl ether (200 mL) was cooled to 0°C under argon. Pyridine (5.7 mL, 50 mmol) was added dropwise with stirring over 5 min. The solution was stirred at 0°C for 15 min, then allowed to warm to room temperature and stirred for three additional hours. The ether solution was filtered, washed with 1 M HC1, and then twice with water, dried over MgS ⁇ 4, filtered, and concentrated on a rotary evaporator to give butyl chloromethyl carbonate (7 g, 85%).
  • Dibutyl PMPA carbonate Anhydrous PMPA (4 g, 13 mmol) and DIEA (10.5 mL, 60 mmol) were placed in anhydrous DMF (40 mL). Butyl chloromethyl carbonate (40 mmol) was then added and the suspension stirred at room temperature for 48 hr. The reaction was then heated to 50°C for 18hr. The DMF was removed on a rotary evaporator, and the reaction partitioned between CH2CI2 (250 mL) and water (250 mL). The CH2CI2 layer was washed once with saturated aqueous NaHC ⁇ 3, dried over magnesium sulfate, filtered, and concentrated on a rotary evaporator.
  • Example 8 Synthesis of Bis Isopropyl Oxymethyl Carbonate of PMPA To a stirred suspension of PMPA (1 g, 3.57 mmol) in DMF (5 mL) were added Et3N (1.5 mL, 10.71 mmol) and chloromethyl isopropyl carbonate (1.67 g, 10.71 mmol). The reaction mixture was then diluted with ethyl acetate (100 mL) and filtered. The filtrate was washed with water (2 x 50 mL) and finally with brine (10 mL). The crude obtained after removal of the solvent was dried under vacuum. The resulting oil was dissolved in isopropanol (7 mL) and citric acid (260 mg) was added. The mixture was stirred for 16 h at room temperature and then cooled to 0°C. The product was crystallized and crystals were filtered and dried. Mp 76-81°C.
  • the solution stability of PMPA carbonates was studied at pH 7.4 at 37°C in 10 mM buffer (NaH 2 P ⁇ 4 and Na2HP ⁇ 4 ) with the total ionic strength adjusted to 0.15 M with KC1.
  • the assays were performed by adding 200 ⁇ L of a PMPA carbonate stock solution (about 1 mg/mL in DMSO) to 10 mL of pre- equilibrated buffer at 37°C. Samples were removed at specific times points and analyzed by HPLC. The chemical 1 1 /2 is expressed in terms of the number of hours required to hydrolyze 50% of the carbonate at the specified pH.
  • PMPA (9-[(R)-2-(phosphonomethoxy)propyl]adenine) and PMPA carbonates were examined to determine the effect of dose on the pharmacokinetics of PMPA in beagle dogs, in particular the bioavailability of PMPA following oral administration to beagle dogs.
  • PMPA monohydrate was synthesized by Gilead Sciences.
  • Tetrabutylammonium hydrogen phosphate (TBAHP) was obtained from Fluka (Ronkonkoma, NY). Acetonitrile was obtained from Baxter (Muskegon, MI). Dibasic potassium phosphate, monobasic potassium phosphate, and sodium acetate trihydrate were obtained from Mallinckrodt (Paris, KY). Chloroacetaldehyde and trifluoroacetic acid (TFA) were from Aldrich (Milwaukee, WI).
  • the intravenous formulations used as standards were isotonic aqueous solutions containing 50 mg/mL PMPA.
  • Compound was added to 10 mL of WFI (water for injection from Abbott Laboratory) and IN NaOH was added to adjust the pH to 7.4.
  • the solutions were diluted to 15 mL with WFI and sterile filtered with a 0.2 ⁇ m filter.
  • the PMPA dose was 10 mg/kg (0.2 mL/kg).
  • the intravenous formulation for a 1 mg/kg dose was prepared as described above except only 75 mg of PMPA was added to WFI and the final concentration was 5 mg/mL. The dose was 1 mg/kg (0.2 mL/kg).
  • Oral formulation of carbonates were prepared in 20-40% PEG 400/50 mM citric acid and were adjusted to pH 2.2. Doses ranged from 6.2-10 mg eq of PMPA/kg and are shown in Table 1.
  • pentagastrin pretreatment dogs were given a single intramuscular injection of pentagastrin (Peptavlon 0.25 mg/mL, Ayerst Laboratories, Inc., Philadelphia, PA) at a dose of 6 ⁇ g/kg, 20 minutes prior to dosing. Water was provided ad lib.
  • Each formulation was administered as a single dose to five male beagle dogs. Individual vials of each formulation were provided for each animal. The intravenous formulation was administrated via a cephalic vein. The oral suspension was administered by gavage, followed by two 10 mL water washes. At least one week washout period was allowed between administrations.
  • Plasma samples (4.0 mL) were collected by direct jugular access from each animal into heparinized tubes. Animals remained conscious throughout the sample collection period. Blood was processed immediately for plasma by centrifugation at 2000 rpm for 10 minutes. Plasma samples were frozen and maintained at ⁇ -20°C until analyzed.
  • Urine samples were collected over 0-24 and 24-48 hours time periods. Urine samples from 0-24 and 24-48 hours were divided into aliquots and mixed based on the volume collected and analyzed to determine amount of PMPA recovered from urine during 0-48 hours.
  • PMPA in Plasma and Urine was determined as follows.
  • PMEA (9-(2- phosphono-methoxyethyl)adenine; adefovir) was used as the internal standard for both analyses.
  • the total concentration of PMPA in dog plasma or urine samples was determined by derivatizing PMPA and PMEA with chloroacetaldehyde to yield a highly fluorescent N 1 , N 6 -ethenoadenine derivative as described (Russell, J. et al. (1991) Determination of 9-[(2- Phosphonylmethoxy)-ethyl]Adenine in Rat Urine by High-Performance Liquid Chromatography with Fluorescence Detection. /. Chromatogr. (Netherlands), 572, 321-326.).
  • Plasma 200 ⁇ L
  • internal standard 20 ⁇ L of 10 ⁇ g/mL PMEA providing a final PMEA concentration of 1 ⁇ g/mL
  • Samples were then evaporated to dryness under reduced pressure at room temperature (Savant SpeedVac).
  • Urine samples (20 ⁇ L) and internal standard (30 ⁇ L of 10 ⁇ g/mL PMEA providing a final PMEA concentration of 1.5 ⁇ g/mL) were used directly for derivatization without drying. The samples were derivatized for analysis as follows.
  • Dried plasma samples or urine samples were reconstituted or mixed in 200 ⁇ L derivatization cocktail (0.34% chloroacetaldehyde in 100 mM sodium acetate, pH 4.5), vortexed, and centrifuged for 10 minutes at 14,000 rpm in an Eppendorf Centrifuge 5402. Supernatant was then transferred to a clean screw capped tube and incubated at 95 ° C for 40 minutes. Derivatized samples were quenched on ice and evaporated to dryness under reduced pressure at room temperature. Dried samples were reconstituted in 200 ⁇ L Mobile Phase A (see below), vortexed and centrifuged for 10 minutes at 14,000 rpm in an Eppendorf Centrifuge 5402. The supernatant was then transferred to autoinjector vials for HPLC analysis.
  • derivatization cocktail 0.34% chloroacetaldehyde in 100 mM sodium acetate, pH 4.5
  • the plasma and urine samples were analyzed by HPLC with Fluorescence Detection as follows.
  • the HPLC system comprised a Model P4000 solvent delivery system with a Model AS3000 autoinjector and a Model F2000 Fluorescence detector (Thermo Separation, San Jose, CA).
  • the column was a Zorbax RX-C18 (5 ⁇ m, 150 x 4.6 mm) (MAC-MOD, Chadds Ford, NY) equipped with a Brownlee RP-18 Newguard guard column (7 ⁇ m, 15 x 3.2 mm) (Alltech, Deerfield, IL).
  • the mobile phases used were: A, 2% acetonitrile in 25 mM potassium phosphate buffer with 5 mM TBAHP, pH 6.0; B, 65% acetonitrile in 25 mM potassium phosphate buffer with 5 mM TBAHP, pH 6.0.
  • the flow rate was 1.5 mL/min and the column temperature was maintained at 35°C by a column oven.
  • the gradient profile was 100% A until 2.0 min, then a linear gradient to 100% B by 13.0 minutes, returning immediately to 100% A.
  • Detection was by fluorescence with excitation at 236 nm and emission at 420 nm, and the injection volume was 50 ⁇ L. Total cycle time between injections was 25 min. Data was acquired and stored by a Peak Pro data acquisition system (Beckman, Palo Alto, CA).
  • CL Dose/AUC (O- ⁇ ) ; where CL is the total plasma clearance.
  • Vss CL x MRT ; where Vss is the apparent volume of distribution at steady state. MRT is the mean residence time.
  • the initial plasma concentration (Co) was determined by extrapolation of log transformed data to zero time. Bioavailability was expressed as
  • Dog liver was obtained fresh from Pharmakon USA (Waverly, PA). Liver homogenate was prepared following a standard protocol. Dog liver was rinsed three times with ice-cold 50 mM sodium/potassium phosphate buffer and homogenized with a Tekmar Tissumizer homogenizer (VWR 33995-060). The homogenate was centrifuged at 9000 g ( 11,000 rpm for Eppendorf Centrifuge 5402; Brinkmann Instruments, Westbury, NY) at 4°C for 20 minutes. The supernatant was designated as the S9 fraction. The concentration of protein in the S9 fraction was determined using a Bio-Rad Protein Assay Kit II, with bovine serum albumin as standard.
  • Esterase activity was determined using o-nitrophenyl butyrate as substrate and activity was calculated based on the increase in absorbance at 420 nm after a 1 min incubation. The homogenates were stored as 1.0 mL aliquots at -70°C.
  • Intestinal Homogenate Dog intestinal segments (jejunum /ileum) were obtained fresh from Pharmakon USA (Waverly, PA) and intestinal homogenate was prepared as described for liver. The intestinal homogenates were stored as 1.0 mL aliquots at -70°C.
  • Human intestinal homogenate (S9) was obtained from Keystone Skin Bank (Exton, PA) at concentration of 20 mg protein/mL.
  • PMPA (9-[(R)-2-(phosphonomethoxy)propyl]adenine) and PMPA carbonates were examined to determine their activity against HIV-1.
  • the increased activity can be attributed to increased cellular uptake of the prodrugs followed by effective intracellular conversion to PMPA, which undergoes subsequent phosphorylation to the antivirally active diphosphate metabolite.
  • the t-butyl carbonate 5d exhibited only 2.5 fold increased activity over PMPA with reduced selectivity possibly due to chemical instability.
  • the antiviral activity data indicate good permeability of alkyl methyl carbonate prodrugs into cells, possibly due to their increased lipophilicity.
  • IC50 50% inhibitory concentration
  • ⁇ CCso Concentration to kill 50% of the cells
  • C SI Selectivity Index(CC5 ⁇ /IC5 ⁇ )
  • n.d - not determined DMSO used as control.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Nouveaux composés comprenant des esters d'analogues de nucléotides de phosphométhoxy antiviraux comportant soit des carbonates, soit des carbamates représentés par la structure -OC(R2)2OC(O)X(R)a, dans laquelle R2 indépendamment représente H, alkyle C¿1?-C12, aryle, alkényle, alkynyle, alkyenylaryle, alkynylaryle, alkaryle, arylalkynyle, arylalkényle ou arylalkyle non substitué ou substitué par halo, azido, nitro ou OR?3¿ dans laquelle R3 représente alkyle C¿1?-C12; X représente N ou O; R représente indépendamment H, alkyle C1-C12, aryle, alkényle, alkynyle, alkyenylaryle, alkynylaryle, alkaryle, arylalkynyle, arylalkényle ou arylalkyle non substitué ou substitué par halo, azido, nitro, -O-, -N=, -NR?4-, -N(R4)¿2- ou OR3; R4 indépendamment représente -H ou alkyle C¿1?-C8, à condition qu'au moins un R ne représente pas H; a est 1 ou 2, à condition que, quand a est 2 et X représente N, (a) deux groupes R puissent être pris ensemble afin de constituer un carbocycle ou un hétérocycle contenant oxygène, ou (b) un R, de plus, puisse être OR?3¿. Ces composés sont utiles en tant qu'intermédiaires pour la préparation de composés antiviraux ou d'oligonucléotides ou sont utiles pour une administration directe au patient dans le cas d'une thérapie ou d'une prophylaxie antivirales. Des modes de réalisation sont particulièrement efficaces quand ils sont administrés oralement.
PCT/US1997/013244 1996-07-26 1997-07-25 Analogues de nucleotides WO1998004569A1 (fr)

Priority Applications (16)

Application Number Priority Date Filing Date Title
AT97936257T ATE240339T1 (de) 1996-07-26 1997-07-25 Nukleotidanaloga
AU38970/97A AU713374B2 (en) 1996-07-26 1997-07-25 Nucleotide analogs
JP50831898A JP4033494B2 (ja) 1996-07-26 1997-07-25 ヌクレオチドアナログ
CA002261619A CA2261619C (fr) 1996-07-26 1997-07-25 Analogues de nucleotides
EP97936257A EP0915894B1 (fr) 1996-07-26 1997-07-25 Analogues de nucleotides
DK97936257T DK0915894T3 (da) 1996-07-26 1997-07-25 Nukleotidanaloger
NZ333687A NZ333687A (en) 1996-07-26 1997-07-25 Phosphonomethoxy nucleotide analogs
DE69722004T DE69722004T2 (de) 1996-07-26 1997-07-25 Nukleotidanaloga
DE200512000041 DE122005000041I2 (de) 1996-07-26 1997-07-25 Nukleotidanaloga.
DE122008000033C DE122008000033I1 (de) 1996-07-26 1997-07-25 Nukleotidanaloga
HK99105370A HK1020964A1 (en) 1996-07-26 1999-11-19 Nucleotide analogs
LU91178C LU91178I2 (fr) 1996-07-26 2005-06-22 Emtricitabine / Tenofovir Disoproxil et ses dérivés pharmaceutiquement acceptables (TRUVADA).
NL300202C NL300202I1 (nl) 1996-07-26 2005-07-13 Nucleotide-analogen.
FR05C0032C FR05C0032I2 (fr) 1996-07-26 2005-07-19 Analogues de nucleotides
LU91433C LU91433I2 (fr) 1996-07-26 2008-04-30 "Tenofovir disoproxil et les sels, en particulier le fumarate, hydrates, tautomers et solvates en combination avec l'emtricitabine et l'efavirenz (ATRIPLA)
NL300344C NL300344I1 (nl) 1996-07-26 2008-05-13 Nucleotide-analogen

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US2270896P 1996-07-26 1996-07-26
US68683896A 1996-07-26 1996-07-26
US08/686,838 1996-07-26
US60/022,708 1996-07-26

Publications (1)

Publication Number Publication Date
WO1998004569A1 true WO1998004569A1 (fr) 1998-02-05

Family

ID=26696272

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1997/013244 WO1998004569A1 (fr) 1996-07-26 1997-07-25 Analogues de nucleotides

Country Status (4)

Country Link
JP (6) JP4033494B2 (fr)
CA (1) CA2261619C (fr)
TW (2) TW470748B (fr)
WO (1) WO1998004569A1 (fr)

Cited By (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999005150A1 (fr) * 1997-07-25 1999-02-04 Gilead Sciences, Inc. Composition d'analogues de nucleotides et procede de synthese
EP1243593A2 (fr) * 1997-07-25 2002-09-25 Gilead Sciences, Inc. Composition d'analogues de nucléotides et procédé de synthèse
EP1301519A2 (fr) 2000-07-21 2003-04-16 Gilead Sciences, Inc. Promedicaments a base d'analogues nucleotidiques de phosphonate et leurs methodes de selection et d'elaboration
WO2004096234A2 (fr) * 2003-04-25 2004-11-11 Gilead Sciences, Inc. Analogues de phosphonate inhibiteurs de kinase
WO2004111064A1 (fr) 2003-06-16 2004-12-23 Institute Of Organic Chemistry And Biochemistry, Academy Of Sciences Of The Czech Republic Composés de pyrimidine à groupes phosphonate, en tant qu'analogues nucleotidiques antiviraux
WO2005039552A2 (fr) * 2003-10-24 2005-05-06 Gilead Sciences, Inc. Derives de phosphonate a usage therapeutique
WO2005063258A1 (fr) * 2003-12-22 2005-07-14 Gilead Sciences, Inc. Conjugues de phosphonate inhibant la kinase
KR100700089B1 (ko) * 1997-07-25 2007-03-28 길리애드 사이언시즈, 인코포레이티드 뉴클레오티드 동족체의 제조에 사용되는 중간체의 제조방법
US7273715B2 (en) 2003-10-24 2007-09-25 Gilead Sciences, Inc. Methods and compositions for identifying therapeutic compounds with GS-9005 ester hydrolase A
US7300924B2 (en) 2003-04-25 2007-11-27 Gilead Sciences, Inc. Anti-infective phosphonate analogs
US7407965B2 (en) 2003-04-25 2008-08-05 Gilead Sciences, Inc. Phosphonate analogs for treating metabolic diseases
US7427624B2 (en) 2003-10-24 2008-09-23 Gilead Sciences, Inc. Purine nucleoside phosphorylase inhibitory phosphonate compounds
US7427636B2 (en) 2003-04-25 2008-09-23 Gilead Sciences, Inc. Inosine monophosphate dehydrogenase inhibitory phosphonate compounds
US7429565B2 (en) 2003-04-25 2008-09-30 Gilead Sciences, Inc. Antiviral phosphonate analogs
US7432261B2 (en) 2003-04-25 2008-10-07 Gilead Sciences, Inc. Anti-inflammatory phosphonate compounds
US7432272B2 (en) 2003-12-22 2008-10-07 Gilead Sciences, Inc. Antiviral analogs
US7432273B2 (en) 2003-10-24 2008-10-07 Gilead Sciences, Inc. Phosphonate analogs of antimetabolites
US7452901B2 (en) 2003-04-25 2008-11-18 Gilead Sciences, Inc. Anti-cancer phosphonate analogs
US7462608B2 (en) 2002-04-26 2008-12-09 Gilead Sciences, Inc. Non nucleoside reverse transcriptase inhibitors
US7470724B2 (en) 2003-04-25 2008-12-30 Gilead Sciences, Inc. Phosphonate compounds having immuno-modulatory activity
WO2009064174A1 (fr) * 2007-11-14 2009-05-22 Ultimorphix Technologies B.V. Forme polymorphe du ténofovir disoproxil fumarate, son procédé de préparation et son utilisation
US7645747B2 (en) 2003-04-25 2010-01-12 Gilead Sciences, Inc. Therapeutic phosphonate compounds
JP2010280724A (ja) * 1998-06-24 2010-12-16 Emory Univ Ｈｉｖの治療薬物の製造のための他の抗ｈｉｖ薬と組み合わせた３’−アジド−２’，３’−ジデオキシウリジンの使用
EP2420238A2 (fr) 2007-04-13 2012-02-22 Southern Research Institute Agents anti-angiogéniques
WO2012152317A1 (fr) * 2011-05-10 2012-11-15 Okapi Sciences Nv Composés destinés à être utilisés dans le traitement d'infections rétrovirales chez les félins
US8592397B2 (en) 2003-01-14 2013-11-26 Gilead Sciences, Inc. Compositions and methods for combination antiviral therapy
US8598185B2 (en) 2005-06-13 2013-12-03 Bristol-Myers Squibb & Gilead Sciences, Inc. Unitary pharmaceutical dosage form
CN103626802A (zh) * 2012-08-23 2014-03-12 重庆药友制药有限责任公司 一种制备替诺福韦的新方法
US8754065B2 (en) 2011-08-16 2014-06-17 Gilead Sciences, Inc. Tenofovir alafenamide hemifumarate
US8871271B2 (en) 2005-06-13 2014-10-28 Gilead Sciences, Inc. Method and composition for pharmaceutical product
US8951986B2 (en) 2008-07-08 2015-02-10 Gilead Sciences, Inc. Salts of HIV inhibitor compounds
EP2860185A1 (fr) 2013-10-09 2015-04-15 Zentiva, k.s. Procédé amélioré pour la préparation du Ténofovir disoproxil et ses sels pharmaceutiquement acceptables
WO2015051875A1 (fr) 2013-10-09 2015-04-16 Zentiva, K.S. Sel dihydrogénophosphate de ténofovir disoproxil
US9187507B2 (en) 2009-12-10 2015-11-17 Institute Of Pharmacology And Toxicology Academy Of Military Medical Sciences P.L.A. China Acyclic nucleoside phosphonate derivatives and medical uses thereof
US9227990B2 (en) 2012-10-29 2016-01-05 Cipla Limited Antiviral phosphonate analogues and process for preparation thereof
US9457035B2 (en) 2004-07-27 2016-10-04 Gilead Sciences, Inc. Antiviral compounds
US9908908B2 (en) 2012-08-30 2018-03-06 Jiangsu Hansoh Pharmaceutical Co., Ltd. Tenofovir prodrug and pharmaceutical uses thereof
CN107805202A (zh) * 2017-12-01 2018-03-16 内蒙古圣氏化学股份有限公司 一种氯甲基异丙基碳酸酯连续化反应装置及方法
US10851125B2 (en) 2017-08-01 2020-12-01 Gilead Sciences, Inc. Crystalline forms of ethyl ((S)-((((2R,5R)-5-(6-amino-9H-purin-9-yl)-4-fluoro-2,5-dihydrofuran-2-yl)oxy)methyl)(phenoxy)phosphoryl(-L-alaninate

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4033494B2 (ja) * 1996-07-26 2008-01-16 ギリヤド サイエンシーズ， インコーポレイテッド ヌクレオチドアナログ
US20100216822A1 (en) * 2005-06-13 2010-08-26 Brightgene Bio-Medical Technology Co., Ltd. Nucleotide Analogue Prodrug and the Preparation Thereof
US20090270352A1 (en) * 2007-05-22 2009-10-29 Ultimorphix Technologies B.V. Tenofovir Disoproxil Hemi-Fumaric Acid Co-Crystal
JP5757860B2 (ja) * 2008-04-25 2015-08-05 シプラ・リミテッド 結晶形態のテノホビルジソプロキシル及びその製造方法
TWI660965B (zh) * 2014-01-15 2019-06-01 美商基利科學股份有限公司 泰諾福韋之固體形式

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0481214A1 (fr) * 1990-09-14 1992-04-22 Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic Pro-médicaments dérivés de phosphonates
WO1992009611A1 (fr) * 1990-12-01 1992-06-11 Beecham Group Plc Produits pharmaceutiques
WO1995007920A1 (fr) * 1993-09-17 1995-03-23 Gilead Sciences, Inc. Analogues de nucleotides

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL84477A (en) * 1986-11-18 1995-12-08 Bristol Myers Squibb Co History of Phosphonomethoxyalkylene Purinopyrimidine and Pharmaceutical Preparations Containing Them
JP4033494B2 (ja) * 1996-07-26 2008-01-16 ギリヤド サイエンシーズ， インコーポレイテッド ヌクレオチドアナログ

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0481214A1 (fr) * 1990-09-14 1992-04-22 Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic Pro-médicaments dérivés de phosphonates
WO1992009611A1 (fr) * 1990-12-01 1992-06-11 Beecham Group Plc Produits pharmaceutiques
WO1995007920A1 (fr) * 1993-09-17 1995-03-23 Gilead Sciences, Inc. Analogues de nucleotides

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
LINDAHL A ET AL: "Synthesis of an acryloxymethyl prodrug of the inositol phosphate.alpha.-trinositol", J. CARBOHYDR. CHEM. (JCACDM,07328303);96; VOL.15 (5); PP.549-554, PERSTORP PHARMA;PERSTORP; S-284 80; SWED. (SE), XP002043027 *

Cited By (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999005150A1 (fr) * 1997-07-25 1999-02-04 Gilead Sciences, Inc. Composition d'analogues de nucleotides et procede de synthese
EP1243593A2 (fr) * 1997-07-25 2002-09-25 Gilead Sciences, Inc. Composition d'analogues de nucléotides et procédé de synthèse
EP1243590A2 (fr) * 1997-07-25 2002-09-25 Gilead Sciences, Inc. Composition d'analogues de nucléotides et procédé de synthèse
EP1243593A3 (fr) * 1997-07-25 2002-12-04 Gilead Sciences, Inc. Composition d'analogues de nucléotides et procédé de synthèse
EP1243590A3 (fr) * 1997-07-25 2002-12-18 Gilead Sciences, Inc. Composition d'analogues de nucléotides et procédé de synthèse
KR100700087B1 (ko) * 1997-07-25 2007-03-28 길리애드 사이언시즈, 인코포레이티드 뉴클레오티드 동족체의 제조 방법
KR100700089B1 (ko) * 1997-07-25 2007-03-28 길리애드 사이언시즈, 인코포레이티드 뉴클레오티드 동족체의 제조에 사용되는 중간체의 제조방법
JP2010280724A (ja) * 1998-06-24 2010-12-16 Emory Univ Ｈｉｖの治療薬物の製造のための他の抗ｈｉｖ薬と組み合わせた３’−アジド−２’，３’−ジデオキシウリジンの使用
EP2682397B1 (fr) 2000-07-21 2017-04-19 Gilead Sciences, Inc. Promédicaments d'analogues de nucléotides phosphonatés et procédés permettant de sélectionner et fabriquer ceux-ci
CZ304886B6 (cs) * 2000-07-21 2015-01-07 Gilead Sciences, Inc. Prekurzory léčiv na bázi fosfonátových analogů nukleotidů a způsoby jejich výběru a přípravy
EP1301519B2 (fr) † 2000-07-21 2021-11-10 Gilead Sciences, Inc. Promedicaments a base d'analogues nucleotidiques de phosphonate et leurs methodes de selection et d'elaboration
EP1301519A2 (fr) 2000-07-21 2003-04-16 Gilead Sciences, Inc. Promedicaments a base d'analogues nucleotidiques de phosphonate et leurs methodes de selection et d'elaboration
JP2009062383A (ja) * 2000-07-21 2009-03-26 Gilead Sciences Inc ホスホネートヌクレオチドアナログのプロドラッグならびにこれを選択および作製するための方法。
US7649015B2 (en) 2002-04-26 2010-01-19 Gilead Sciences, Inc. Cellular accumulation of phosphonate analogs of HIV protease inhibitor compounds
US7462608B2 (en) 2002-04-26 2008-12-09 Gilead Sciences, Inc. Non nucleoside reverse transcriptase inhibitors
US9457036B2 (en) 2003-01-14 2016-10-04 Gilead Sciences, Inc. Compositions and methods for combination antiviral therapy
US8592397B2 (en) 2003-01-14 2013-11-26 Gilead Sciences, Inc. Compositions and methods for combination antiviral therapy
US9744181B2 (en) 2003-01-14 2017-08-29 Gilead Sciences, Inc. Compositions and methods for combination antiviral therapy
US7300924B2 (en) 2003-04-25 2007-11-27 Gilead Sciences, Inc. Anti-infective phosphonate analogs
US7452901B2 (en) 2003-04-25 2008-11-18 Gilead Sciences, Inc. Anti-cancer phosphonate analogs
US7417055B2 (en) 2003-04-25 2008-08-26 Gilead Sciences, Inc. Kinase inhibitory phosphonate analogs
WO2004096234A3 (fr) * 2003-04-25 2005-01-27 Gilead Sciences Inc Analogues de phosphonate inhibiteurs de kinase
US7427636B2 (en) 2003-04-25 2008-09-23 Gilead Sciences, Inc. Inosine monophosphate dehydrogenase inhibitory phosphonate compounds
US7429565B2 (en) 2003-04-25 2008-09-30 Gilead Sciences, Inc. Antiviral phosphonate analogs
US7432261B2 (en) 2003-04-25 2008-10-07 Gilead Sciences, Inc. Anti-inflammatory phosphonate compounds
US8871785B2 (en) 2003-04-25 2014-10-28 Gilead Sciences, Inc. Antiviral phosphonate analogs
US7407965B2 (en) 2003-04-25 2008-08-05 Gilead Sciences, Inc. Phosphonate analogs for treating metabolic diseases
US8022083B2 (en) 2003-04-25 2011-09-20 Gilead Sciences, Inc. Antiviral phosphonate analogs
US7273716B2 (en) 2003-04-25 2007-09-25 Gilead Sciences, Inc. Methods and compositions for identifying therapeutic compounds with GS-7340 ester hydrolase
US7470724B2 (en) 2003-04-25 2008-12-30 Gilead Sciences, Inc. Phosphonate compounds having immuno-modulatory activity
WO2004096234A2 (fr) * 2003-04-25 2004-11-11 Gilead Sciences, Inc. Analogues de phosphonate inhibiteurs de kinase
US9139604B2 (en) 2003-04-25 2015-09-22 Gilead Sciences, Inc. Antiviral phosphonate analogs
US7645747B2 (en) 2003-04-25 2010-01-12 Gilead Sciences, Inc. Therapeutic phosphonate compounds
WO2004111064A1 (fr) 2003-06-16 2004-12-23 Institute Of Organic Chemistry And Biochemistry, Academy Of Sciences Of The Czech Republic Composés de pyrimidine à groupes phosphonate, en tant qu'analogues nucleotidiques antiviraux
US7115592B2 (en) 2003-06-16 2006-10-03 Institute Of Organic Chemistry Phosphonate substituted pyrimidine compounds and methods for therapy
US7273715B2 (en) 2003-10-24 2007-09-25 Gilead Sciences, Inc. Methods and compositions for identifying therapeutic compounds with GS-9005 ester hydrolase A
WO2005039552A2 (fr) * 2003-10-24 2005-05-06 Gilead Sciences, Inc. Derives de phosphonate a usage therapeutique
US7427624B2 (en) 2003-10-24 2008-09-23 Gilead Sciences, Inc. Purine nucleoside phosphorylase inhibitory phosphonate compounds
WO2005039552A3 (fr) * 2003-10-24 2005-06-09 Gilead Sciences Inc Derives de phosphonate a usage therapeutique
US7273717B2 (en) 2003-10-24 2007-09-25 Gilead Sciences, Inc. Methods and compositions for identifying therapeutic compounds with GS-9005 ester hydrolase B
US7432273B2 (en) 2003-10-24 2008-10-07 Gilead Sciences, Inc. Phosphonate analogs of antimetabolites
US7432272B2 (en) 2003-12-22 2008-10-07 Gilead Sciences, Inc. Antiviral analogs
WO2005063258A1 (fr) * 2003-12-22 2005-07-14 Gilead Sciences, Inc. Conjugues de phosphonate inhibant la kinase
US9579332B2 (en) 2004-07-27 2017-02-28 Gilead Sciences, Inc. Phosphonate analogs of HIV inhibitor compounds
US9457035B2 (en) 2004-07-27 2016-10-04 Gilead Sciences, Inc. Antiviral compounds
US8598185B2 (en) 2005-06-13 2013-12-03 Bristol-Myers Squibb & Gilead Sciences, Inc. Unitary pharmaceutical dosage form
US8871271B2 (en) 2005-06-13 2014-10-28 Gilead Sciences, Inc. Method and composition for pharmaceutical product
US9545414B2 (en) 2005-06-13 2017-01-17 Bristol-Myers Squibb & Gilead Sciences, Llc Unitary pharmaceutical dosage form
US9018192B2 (en) 2005-06-13 2015-04-28 Bristol-Myers Squibb & Gilead Sciences, Inc. Unitary pharmaceutical dosage form
EP2420236A2 (fr) 2007-04-13 2012-02-22 Southern Research Institute Agents anti-angiogéniques
EP2420230A2 (fr) 2007-04-13 2012-02-22 Southern Research Institute Agents anti-angiogéniques
EP2420239A2 (fr) 2007-04-13 2012-02-22 Southern Research Institute Agents anti-angiogéniques
EP2420238A2 (fr) 2007-04-13 2012-02-22 Southern Research Institute Agents anti-angiogéniques
WO2009064174A1 (fr) * 2007-11-14 2009-05-22 Ultimorphix Technologies B.V. Forme polymorphe du ténofovir disoproxil fumarate, son procédé de préparation et son utilisation
US9783568B2 (en) 2008-07-08 2017-10-10 Gilead Sciences, Inc. Salts of HIV inhibitor compounds
US8951986B2 (en) 2008-07-08 2015-02-10 Gilead Sciences, Inc. Salts of HIV inhibitor compounds
US9381206B2 (en) 2008-07-08 2016-07-05 Gilead Sciences, Inc. Salts of HIV inhibitor compounds
US9187507B2 (en) 2009-12-10 2015-11-17 Institute Of Pharmacology And Toxicology Academy Of Military Medical Sciences P.L.A. China Acyclic nucleoside phosphonate derivatives and medical uses thereof
WO2012152317A1 (fr) * 2011-05-10 2012-11-15 Okapi Sciences Nv Composés destinés à être utilisés dans le traitement d'infections rétrovirales chez les félins
US8754065B2 (en) 2011-08-16 2014-06-17 Gilead Sciences, Inc. Tenofovir alafenamide hemifumarate
EP2744810B1 (fr) 2011-08-16 2016-10-05 Gilead Sciences, Inc. Hémifumarate de ténofovir alafénamide
US9296769B2 (en) 2011-08-16 2016-03-29 Gilead Sciences, Inc. Tenofovir alafenamide hemifumarate
CN103626802A (zh) * 2012-08-23 2014-03-12 重庆药友制药有限责任公司 一种制备替诺福韦的新方法
US9908908B2 (en) 2012-08-30 2018-03-06 Jiangsu Hansoh Pharmaceutical Co., Ltd. Tenofovir prodrug and pharmaceutical uses thereof
US9227990B2 (en) 2012-10-29 2016-01-05 Cipla Limited Antiviral phosphonate analogues and process for preparation thereof
WO2015051875A1 (fr) 2013-10-09 2015-04-16 Zentiva, K.S. Sel dihydrogénophosphate de ténofovir disoproxil
WO2015051874A1 (fr) 2013-10-09 2015-04-16 Zentiva, K.S. Procédé amélioré pour la préparation de ténofovir disoproxil et des sels pharmaceutiquement acceptables de celui-ci
EP2860185A1 (fr) 2013-10-09 2015-04-15 Zentiva, k.s. Procédé amélioré pour la préparation du Ténofovir disoproxil et ses sels pharmaceutiquement acceptables
US10851125B2 (en) 2017-08-01 2020-12-01 Gilead Sciences, Inc. Crystalline forms of ethyl ((S)-((((2R,5R)-5-(6-amino-9H-purin-9-yl)-4-fluoro-2,5-dihydrofuran-2-yl)oxy)methyl)(phenoxy)phosphoryl(-L-alaninate
CN107805202A (zh) * 2017-12-01 2018-03-16 内蒙古圣氏化学股份有限公司 一种氯甲基异丙基碳酸酯连续化反应装置及方法

Also Published As

Publication number Publication date
CA2261619C (fr) 2006-05-23
JP2015164934A (ja) 2015-09-17
CA2261619A1 (fr) 1998-02-05
JP4033494B2 (ja) 2008-01-16
JP2017031212A (ja) 2017-02-09
TW444020B (en) 2001-07-01
JP2007297406A (ja) 2007-11-15
JP2000515866A (ja) 2000-11-28
TW470748B (en) 2002-01-01
JP2014159450A (ja) 2014-09-04
JP2011016847A (ja) 2011-01-27

Similar Documents

Publication Publication Date Title
CA2261619C (fr) Analogues de nucleotides
USRE38333E1 (en) Antiviral phosphonomethoxy nucleotide analogs having increased oral bioavailability
EP0915894B1 (fr) Analogues de nucleotides
KR100358327B1 (ko) 포스포네이트뉴클레오티드에스테르유도체
CA2298059C (fr) Composition d'analogues de nucleotides et procede de synthese
JP4083691B2 (ja) 抗レトロウィルス性エナンチオマー性ヌクレオチドアナログ
US6767900B2 (en) Phosphonate nucleotide compound
US6194398B1 (en) Phosphonate nucleotide compound
US20060241081A1 (en) Novel compounds and methods for therapy
NZ229002A (en) Purine derivatives and antiviral compositions
US6818633B2 (en) Antiviral compounds and methods for synthesis and therapy
JP2006527702A5 (fr)
JP3580377B2 (ja) ホスホナートヌクレオチドエステル誘導体

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 97197460.8

Country of ref document: CN

AK Designated states

Kind code of ref document: A1

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH HU IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZW AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH KE LS MW SD SZ UG ZW AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 333687

Country of ref document: NZ

ENP Entry into the national phase

Ref document number: 2261619

Country of ref document: CA

Ref document number: 2261619

Country of ref document: CA

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 1997936257

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 1019997000806

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: 1997936257

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 1019997000806

Country of ref document: KR

WWG Wipo information: grant in national office

Ref document number: 1997936257

Country of ref document: EP

WWR Wipo information: refused in national office

Ref document number: 1019997000806

Country of ref document: KR